BALANCE 1,5 % glukoze 1,75 mmol/L kalcija 5.64 g/1 L+ 3.925 g/1 L+ 0.2573 g/1 L+ 0.1017 g/1 L+ 16.5 g/1 L otopina za peritonejsk Bosna Hersek - Hırvatça - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

balance 1,5 % glukoze 1,75 mmol/l kalcija 5.64 g/1 l+ 3.925 g/1 l+ 0.2573 g/1 l+ 0.1017 g/1 l+ 16.5 g/1 l otopina za peritonejsk

fresenius medical care bh,d.o.o.sarajevo - glukoza, kalcijumhlorid, magnezijumhlorid, natrijumhlorid, natrijumlaktat - otopina za peritonejsku dijalizu - 5.64 g/1 l+ 3.925 g/1 l+ 0.2573 g/1 l+ 0.1017 g/1 l+ 16.5 g/1 l - 1000 ml otopine sadrži: 5,640 g natrijumhlorid 3,925 g natrijumlaktat 0,2573 g kalcijumhlorid, dihidrat 0,1017 g magnezijumhlorid, heksahidrat 16,50 g glukoza, monohidrat (što odgovara 15,00 g bezvodne glukoze)

BALANCE 4,25 % glukoze 1,25 mmol/L kalcija 5.64 g/1 L+ 3.925 g/1 L+ 0.1838 g/1 L+ 0.1017 g/1 L+ 46.75 g/1 L otopina za peritonej Bosna Hersek - Hırvatça - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

balance 4,25 % glukoze 1,25 mmol/l kalcija 5.64 g/1 l+ 3.925 g/1 l+ 0.1838 g/1 l+ 0.1017 g/1 l+ 46.75 g/1 l otopina za peritonej

fresenius medical care bh,d.o.o.sarajevo - glukoza, kalcijumhlorid, magnezijumhlorid, natrijumhlorid, natrijumlaktat - otopina za peritonejsku dijalizu - 5.64 g/1 l+ 3.925 g/1 l+ 0.1838 g/1 l+ 0.1017 g/1 l+ 46.75 g/1 l - 1000 ml otopine sadrži: 5,640 g natrijumhlorida 3,925 g natrijumlaktata 0,1838 g kalcijumhlorid, dihidrata 0,1017 g magnezijumhlorid, heksahidrat 46,75 g (što odgovara 42,50 g bezvodne glukoze) glukoza, monohidrata

BALANCE 4,25 % glukoze 1,75 mmol/L kalcija 5.64 g/1 L+ 3.925 g/1 L+ 0.2573 g/1 L+ 0.1017 g/1 L+ 46.75 g/1 L otopina za peritonej Bosna Hersek - Hırvatça - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

balance 4,25 % glukoze 1,75 mmol/l kalcija 5.64 g/1 l+ 3.925 g/1 l+ 0.2573 g/1 l+ 0.1017 g/1 l+ 46.75 g/1 l otopina za peritonej

fresenius medical care bh,d.o.o.sarajevo - glukoza, kalcijumhlorid, magnezijumhlorid, natrijumhlorid, natrijumlaktat - otopina za peritonejsku dijalizu - 5.64 g/1 l+ 3.925 g/1 l+ 0.2573 g/1 l+ 0.1017 g/1 l+ 46.75 g/1 l - 1000 ml otopine sadrži: 5,640 g natrijumhlorida 3,925 g natrijumlaktat 0,2573 g kalcijumhlorid, dihidrat 0,1017 g magnezijumhlorid, heksahidrat 46,75 g (što odgovara 42,50 g bezvodne glukoze) glukoza, monohidrat

Vegzelma Avrupa Birliği - Hırvatça - EMA (European Medicines Agency)

vegzelma

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastična sredstva - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. za daljnje informacije o stanju čovjeka epidermalnog faktora rasta receptora 2 (her2), molimo pogledajte odjeljak 5. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. dodatne informacije o statusu her2 potražite u odjeljku 5. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Zejula Avrupa Birliği - Hırvatça - EMA (European Medicines Agency)

zejula

glaxosmithkline (ireland) limited - niraparib (tosilate monohydrate) - fallopian tube neoplasms; peritoneal neoplasms; ovarian neoplasms - antineoplastična sredstva - zejula is indicated: , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (figo stages iii and iv) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. , as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

Apealea Avrupa Birliği - Hırvatça - EMA (European Medicines Agency)

apealea

inceptua ab - paklitaksela - neoplazme jajnika - antineoplastic agents, taxanes - apealea u kombinaciji s карбоплатином indiciran za liječenje odraslih bolesnika s prvi relaps платиночувствительный эпителиального raka jajnika, primarnog karcinoma брюшины i jajovoda rak.

Zirabev Avrupa Birliği - Hırvatça - EMA (European Medicines Agency)

zirabev

pfizer europe ma eeig - bevacizumab - colorectal neoplasms; breast neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastična sredstva - zirabev u kombinaciji s fluoropyrimidine temelju kemoterapija prikazana za liječenje odraslih bolesnika s метастатической карциномой kolona ili rektuma. zirabev u kombinaciji s paklitaksel je indiciran za prva linija terapije kod odraslih pacijenata s metastaze raka dojke . za više informacija kao i za ljudsko receptor epidermalnog faktora rasta 2 (her2 i) status. zirabev, osim платин-na temelju kemoterapije, dizajniran je za prvu liniju terapije odraslih pacijenata s нерезектабельными-najčešće metastaze ili recidivom немелкоклеточным raka pluća nego drugi uglavnom плоскоклеточной гистологией. zirabev u kombinaciji s interferonom alfa-2a dizajniran za prvu liniju tretmana odraslih pacijenata s raširena i/ili metastaze почечно-клеточным raka. zirabev, u kombinaciji s паклитакселом i цисплатином ili паклитакселом i топотеканом kod pacijenata koji ne mogu dobiti платиновую terapiju, indiciran za liječenje odraslih bolesnika s uporni, relaps ili метастатической карциномой grlića maternice.

Renvela Avrupa Birliği - Hırvatça - EMA (European Medicines Agency)

renvela

sanofi b.v. - sevelamer karbonat - hyperphosphatemia; renal dialysis - svi ostali terapeutski proizvodi - renvela je indicirana za kontrolu hiperfosfatemije kod odraslih osoba koje primaju hemodijalizu ili peritonealnu dijalizu. renvela također je prikazano za kontrolu hyperphosphataemia u odraslih bolesnika s kroničnom bolešću bubrega bez dijalizu s fosfora u serumu ≥ 1. 78 mmol/l. renvela treba koristiti u okviru nekoliko terapijskih pristupa koji se mogu uključiti dodataka kalcija, 1,25-дигидрокси vitamin d3 ili jedan od njegovih analoga za praćenje razvoja bolesti bubrega канальцах .

Renagel Avrupa Birliği - Hırvatça - EMA (European Medicines Agency)

renagel

sanofi b.v. - sevelamer - renal dialysis; hyperphosphatemia - svi ostali terapeutski proizvodi - renagel is indicated for the control of hyperphosphataemia in adult patients receiving  haemodialysis or peritoneal dialysis. renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Velphoro Avrupa Birliği - Hırvatça - EMA (European Medicines Agency)

velphoro

vifor fresenius medical care renal pharma france - sucroferric oxyhydroxide - hyperphosphatemia; renal dialysis - lijekovi za liječenje hiperkalemiju i гиперфосфатемии - velcro je indiciran za kontrolu razine serumskog fosfora u bolesnika s hemodijalizom (hd) ili peritonejskom dijalizom (pd) u odraslih kroničnih bubrežnih bolesti (ckd). velphoro is indicated for the control of serum phosphorus levels in paediatric patients 2 years of age and older with ckd stages 4-5 (defined by a glomerular filtration rate.